Trial Profile
The study for efficacy of teneligliptin in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Teneligliptin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Sep 2018 Status changed from recruiting to completed.
- 10 Mar 2014 New trial record